Clinical Trial Update: CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia has completed, reporting in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology | Conditions: B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED